Correlation between long-term use of metformin and incidence of NAFLD among patients with type 2 diabetes mellitus: A real-world cohort study

The Association between Non-Alcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis with Serological Vitamin B12 Markers: Results from the NHANES 1999–2004

(2022) Li Li et al.   Nutrients

The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement?

(2021) Anna Licata et al.   Nutrients

Taiwan’s National Health Insurance Research Database: past and future

(2019) Cheng-Yang Hsieh et al.   Clinical Epidemiology

Long-term treatment with metformin in the prevention of fatty liver in Zucker diabetic fatty rats

(2019) Yi Sui et al.   Diabetology & Metabolic Syndrome

Folate and B12 Levels Correlate with Histological Severity in NASH Patients

(2018) Mahmud Mahamid et al.   Nutrients

Association of metformin use with vitamin B12 deficiency in the institutionalized elderly

(2018) Chit Wai Wong et al.   ARCHIVES OF GERONTOLOGY AND GERIATRICS

Metformin: An Old Drug with New Applications

(2018) Joseph Zhou et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The association of metformin use with vitamin B12 deficiency and peripheral neuropathy in Saudi individuals with type 2 diabetes mellitus

(2018) Turki J. Alharbi et al.   PLoS One

Of mice and men: Is there a future for metformin in the treatment of hepatic steatosis?

(2018) Charlotte J. Green et al.   DIABETES OBESITY & METABOLISM

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

(2017) Naga Chalasani et al.   HEPATOLOGY

Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus

(2017) Wenjie Dai et al.   MEDICINE

Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease

(2017) Wenhuan Feng et al.   Journal of Diabetes

Metformin improves lipid metabolism disorders through reducing the expression of microsomal triglyceride transfer protein in OLETF rats

(2016) Nianhong Wang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016) et al.   DIABETOLOGIA

Hyperuricaemia and risk of nonalcoholic fatty liver disease: A meta-analysis

(2016) Karn Wijarnpreecha et al.   LIVER INTERNATIONAL

Non-alcoholic fatty liver disease and dyslipidemia: An update

(2016) Niki Katsiki et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Non-alcoholic fatty liver disease and diabetes

(2016) Jonathan M. Hazlehurst et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes

(2016) Gabriele Forlani et al.   Journal of Diabetes Research

Association Between Serum Vitamin B12 Levels and the Degree of Steatosis in Patients With Nonalcoholic Fatty Liver Disease

(2016) Mustafa Koplay et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Metformin inhibits hepatocellular glucose, lipid and cholesterol biosynthetic pathways by transcriptionally suppressing steroid receptor coactivator 2 (SRC-2)

(2015) Andre Madsen et al.   Scientific Reports

Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)

(2014) Iliana Doycheva et al.   ADVANCES IN THERAPY

Metformin Ameliorates Hepatic Steatosis and Inflammation without Altering Adipose Phenotype in Diet-Induced Obesity

(2014) Shih-Lung Woo et al.   PLoS One

Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease

(2013) Yuki Kawano et al.   JOURNAL OF GASTROENTEROLOGY

Metformin-Induced Hepatotoxicity

(2012) F. Miralles-Linares et al.   DIABETES CARE

Metformin protects against the development of fructose-induced steatosis in mice: role of the intestinal barrier function

(2012) Astrid Spruss et al.   LABORATORY INVESTIGATION

Metformin Prevents and Reverses Inflammation in a Non-Diabetic Mouse Model of Nonalcoholic Steatohepatitis

(2012) Yuki Kita et al.   PLoS One

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

(2011) G. Vernon et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?

(2011) Thomas Grimmsmann et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors

(2011) Nathalie C. Leite et al.   LIVER INTERNATIONAL

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

(2010) M. O. Rakoski et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Hepatotoxicity Associated with Metformin Therapy in Treatment of Type 2 Diabetes Mellitus with Nonalcoholic Fatty Liver Disease

(2010) Catherine J Cone et al.   ANNALS OF PHARMACOTHERAPY

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

(2010) Giovanni Musso et al.   HEPATOLOGY

Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications

(2009) Elisa Fabbrini et al.   HEPATOLOGY

Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial

(2009) John Willy Haukeland et al.   SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY

The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial

(2009) William W. Shields et al.   Therapeutic Advances in Gastroenterology

Clinical trial: insulin-sensitizing agents may reduce consequences of insulin resistance in individuals with non-alcoholic steatohepatitis

(2008) R. IDILMAN et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis

(2008) R. LOOMBA et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS